PMV Pharma reports Q3 loss, PC14586 Phase 1 data shows 38% ORR at RP2D

PMV Pharmaceuticals, Inc.

2023-Q3 EPS reported -$1.13

Net loss 9mo $53.2M vs $54.0M YoY; cash $238.1M as of Sep 30, 2023.
PC14586 PYNNACLE: 38% ORR at 2000 mg RP2D (6/16 evaluable, TP53 Y220C/KRAS wild-type).
Median duration of response 7 months across ovarian, breast, prostate, SCLC, endometrial cancers.
Registrational Phase 2 trial to start Q1 2024; RP2D aligned with FDA in Q3 2023 meeting.
Raised $35.1M net via ATM facility during 9mo; R&D expenses increased to $42.5M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PMV Pharmaceuticals, Inc. reported financial results for the third quarter ended September 30, 2023.

Period: the third quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 9, 2023, PMV Pharmaceuticals, Inc. issued a press release announcing its financial results for the third quarter ended September 30, 2023.

View on SEC.gov

22 earnings releases filed in the last 30 days. Browse all earnings releases →

PMV Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-061552

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.